Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Habermann

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Hematology|August 28, 2022
A roadmap for clinical trial design in marginal zone lymphomaJuan Pablo Alderuccio, Thomas Habermann, Russ Kuker, et al.
Blood|August 15, 2002
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)Joseph A Sparano, Edie Weller, Tipu Nazeer, et al.
Frontiers in Oncology|August 7, 2023
Induction treatment in high-grade B-cell lymphoma with a concurrent <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangement: a systematic review and meta-analysisVanja Zeremski, Siegfried Kropf, Michael Koehler, et al.
American Journal of Hematology|October 22, 2021
Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphomaMatthew Ho, Saurabh Zanwar, Patrick Duggan, et al.
Blood Advances|July 18, 2024
Transformation of marginal zone lymphoma to Hodgkin lymphomaKamilia N Moalem, Juan Pablo Alderuccio, Côme Bommier, et al.
British Journal of Haematology|September 12, 2014
Clinical characteristics and healthcare utilization of patients with multicentric Castleman diseaseCorey Casper, Dana Y Teltsch, Don Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology GroupCathy A Coyne, Ronghui Xu, Peter Raich, et al.
Blood Cancer Journal|January 15, 2020
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?Priyanka A Pophali, Lisa M Marinelli, Rhett P Ketterling, et al.
Leukemia & Lymphoma|November 23, 2022
Central nervous system involvement by mantle cell lymphomaNicole McLaughlin, Yucai Wang, Thomas Witzig, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting SeriesGita Thanarajasingam, Ajay Major, Vishal Bhatnagar, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|August 28, 2022
A roadmap for clinical trial design in marginal zone lymphomaJuan Pablo Alderuccio, Thomas Habermann, Russ Kuker, et al.
Blood|August 15, 2002
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)Joseph A Sparano, Edie Weller, Tipu Nazeer, et al.
Frontiers in Oncology|August 7, 2023
Induction treatment in high-grade B-cell lymphoma with a concurrent <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangement: a systematic review and meta-analysisVanja Zeremski, Siegfried Kropf, Michael Koehler, et al.
American Journal of Hematology|October 22, 2021
Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphomaMatthew Ho, Saurabh Zanwar, Patrick Duggan, et al.
Blood Advances|July 18, 2024
Transformation of marginal zone lymphoma to Hodgkin lymphomaKamilia N Moalem, Juan Pablo Alderuccio, Côme Bommier, et al.
British Journal of Haematology|September 12, 2014
Clinical characteristics and healthcare utilization of patients with multicentric Castleman diseaseCorey Casper, Dana Y Teltsch, Don Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology GroupCathy A Coyne, Ronghui Xu, Peter Raich, et al.
Blood Cancer Journal|January 15, 2020
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?Priyanka A Pophali, Lisa M Marinelli, Rhett P Ketterling, et al.
Leukemia & Lymphoma|November 23, 2022
Central nervous system involvement by mantle cell lymphomaNicole McLaughlin, Yucai Wang, Thomas Witzig, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting SeriesGita Thanarajasingam, Ajay Major, Vishal Bhatnagar, et al.
Pageof 4